Researchers created modified versions of psilocin — the active form of psilocybin from “magic mushrooms” — that still target key serotonin pathways linked to depression and other brain disorders but appear to cause far fewer psychedelic-like effects.
Read morePsychedelic Mushrooms Are Getting Stronger
Cultivators are turning to genetic sequencing and cellular-manipulation techniques to breed highly potent mushrooms—leaving some unprepared psychonauts in distress.
Read moreAn Inside Look at One of the First Magic Mushroom Schools in the US
At a forest facility in Oregon, the first US state to allow supervised use of the drug, students work toward becoming licensed trip facilitators.
Read moreMicrodosing Mushrooms? Results Are Still Mixed.
Microdosing psychedelics has benefits, users say. Science isn’t convinced.
Read moreMore on the Therapeutic Potential of Mushrooms
Fred Barrett, a neuroscientist at the Johns Hopkins Center for Psychedelic & Consciousness Research, discusses the revolutionary healing potential of psilocybin, what is not yet known about the compound’s role in treating various psychiatric disorders, the importance of the “therapy” aspect of psychedelic-assisted therapy, and the hurdles that remain to this treatment being accessible to the general public.
Read moreUpdate on Oregon
It has shown to be effective in treating post-traumatic stress disorder, depression and end-of-life anxiety.
Since then, regulations and restrictions for psilocybin treatment have taken shape across the state with many rural counties opting out of providing any psilocybin-related services at all.
Read moreAthletes Turning to Mushrooms
Pain, hope and science collide as athletes turn to magic mushrooms. What do you think?
Read moreTo Trip or Not to Trip?
Inside the scientific debate that’s shaping the future of psychedelic therapy: To trip or not to trip?
Can the magic be removed from the mushroom — and should it?
Read moreOregon Update...
Global Survey 2020 Results: Self-Treatment of LSD and Psilocybin
Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.
High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.
Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.
Read morePsilocybin Mushrooms and Bipolar Disorder
A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder.
The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms.
Read more